Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - rifampicin 300mg - capsule - 300 mg - active: rifampicin 300mg excipient: magnesium stearate maize starch - tuberculosis rifampicin is indicated in the treatment of all forms of tuberculosis, including fresh, advanced, chronic and drug resistant cases. rifampicin should be used in conjunction with at least one other antituberculosis medicine. leprosy rifampicin is indicated in the treatment of multibacillary and paucibacillary leprosy to effect a conversion of the infectious state to a non-infectious state. rifampicin should be used in conjunction with at least one other anti-leprosy drug. methicillin-resistant staphylococcal infections (mrsa) rifampicin can be used as an alternative to vancomycin in the treatment of mrsa. in such circumstances an appropriate companion antibiotic (e.g. fusidic acid) should always be employed. serious staphylococcal infections rifampicin has been used for the treatment of both life-threatening and serious staphylococcal infections. in such circumstances an appropriate companion antibiotic should be employed. brucellosis rifampicin may be used for the treatment of brucellosis. in such circumstances doxycycline should also be used. meningococcal carriers rifampicin is indicated for the treatment of asymptomatic carriers of n. meningitidis to eliminate meningococci from the nasopharynx. (rifampicin is not indicated for the treatment of meningococcal infection because of the possibility of the rapid emergence of resistant organisms). haemophilus influenzae rifampicin is indicated for the treatment of asymptomatic carriers of h influenzae and as chemoprophylaxis of exposed children of 4 years of age or younger. other infections infections caused by rifampicin-sensitive microorganisms such as staphylococci, streptococci, n gonorrhoeae, proteus sp., h. influenzae, e. coli and legionella sp. to prevent emergence of resistant organisms, rifampicin should be given with another antibacterial agent to which the organism has been shown to be susceptible.

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - rifampicin 20 mg/ml (5% overage is added.) - oral suspension - 100 mg/5ml - active: rifampicin 20 mg/ml (5% overage is added.) excipient: agar diolamine methyl hydroxybenzoate polysorbate 80 potassium sorbate propyl hydroxybenzoate purified water raspberry saccharin sodium metabisulfite sucrose - tuberculosis rifampicin is indicated in the treatment of all forms of tuberculosis, including fresh, advanced, chronic and drug resistant cases. rifampicin should be used in conjunction with at least one other antituberculosis medicine. leprosy rifampicin is indicated in the treatment of multibacillary and paucibacillary leprosy to effect a conversion of the infectious state to a non-infectious state. rifampicin should be used in conjunction with at least one other anti-leprosy drug. methicillin-resistant staphylococcal infections (mrsa) rifampicin can be used as an alternative to vancomycin in the treatment of mrsa. in such circumstances an appropriate companion antibiotic (e.g. fusidic acid) should always be employed. serious staphylococcal infections rifampicin has been used for the treatment of both life-threatening and serious staphylococcal infections. in such circumstances an appropriate companion antibiotic should be employed. brucellosis rifampicin may be used for the treatment of brucellosis. in such circumstances doxycycline should also be used. meningococcal carriers rifampicin is indicated for the treatment of asymptomatic carriers of n. meningitidis to eliminate meningococci from the nasopharynx. (rifampicin is not indicated for the treatment of meningococcal infection because of the possibility of the rapid emergence of resistant organisms). haemophilus influenzae rifampicin is indicated for the treatment of asymptomatic carriers of h influenzae and as chemoprophylaxis of exposed children of 4 years of age or younger. other infections infections caused by rifampicin-sensitive microorganisms such as staphylococci, streptococci, n gonorrhoeae, proteus sp., h. influenzae, e. coli and legionella sp. to prevent emergence of resistant organisms, rifampicin should be given with another antibacterial agent to which the organism has been shown to be susceptible.

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - rifampicin 600mg - injection with diluent - 600 mg - active: rifampicin 600mg excipient: sodium formaldehydesulfoxylate sodium hydroxide water for injection polysorbate 80 water for injection - tuberculosis rifampicin is indicated in the treatment of all forms of tuberculosis, including fresh, advanced, chronic and drug resistant cases. rifampicin should be used in conjunction with at least one other antituberculosis medicine. leprosy rifampicin is indicated in the treatment of multibacillary and paucibacillary leprosy to effect a conversion of the infectious state to a non-infectious state. rifampicin should be used in conjunction with at least one other anti-leprosy drug. methicillin-resistant staphylococcal infections (mrsa) rifampicin can be used as an alternative to vancomycin in the treatment of mrsa. in such circumstances an appropriate companion antibiotic (e.g. fusidic acid) should always be employed. serious staphylococcal infections rifampicin has been used for the treatment of both life-threatening and serious staphylococcal infections. in such circumstances an appropriate companion antibiotic should be employed. brucellosis rifampicin may be used for the treatment of brucellosis. in such circumstances doxycycline should also be used. meningococcal carriers rifampicin is indicated for the treatment of asymptomatic carriers of n. meningitidis to eliminate meningococci from the nasopharynx. (rifampicin is not indicated for the treatment of meningococcal infection because of the possibility of the rapid emergence of resistant organisms). haemophilus influenzae rifampicin is indicated for the treatment of asymptomatic carriers of h influenzae and as chemoprophylaxis of exposed children of 4 years of age or younger. other infections infections caused by rifampicin-sensitive microorganisms such as staphylococci, streptococci, n gonorrhoeae, proteus sp., h. influenzae, e. coli and legionella sp. to prevent emergence of resistant organisms, rifampicin should be given with another antibacterial agent to which the organism has been shown to be susceptible.

Јужноафричка Република - Енглески - South African Health Products Regulatory Authority (SAHPRA)

afrivet business management (pty) ltd - injection - see ingredients - each 1.0 ml solution contains marbofloxacin a 100.0 mg - c 170106. quinolones

Јужноафричка Република - Енглески - South African Health Products Regulatory Authority (SAHPRA)

afrivet business management (pty) ltd - tablet - 5 mg - each 1.0ml contains: marbofloxacin 5.0 mg - c.17.1.6 antimicrobials (quinolones)

Јужноафричка Република - Енглески - South African Health Products Regulatory Authority (SAHPRA)

afrivet business management (pty) ltd - tablet - 20 mg - each 1.0ml contains: marbofloxacin 20.0 mg - c.17.1.6 antimicrobials (quinolones)

Јужноафричка Република - Енглески - South African Health Products Regulatory Authority (SAHPRA)

afrivet business management (pty) ltd - tablet - 80 mg - each 1.0ml contains: marbofloxacin 80.0 mg - c.17.1.6 antimicrobials (quinolones)

Аустралија - Енглески - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - trimethoprim; sulfadiazine - parenteral liquid/solution/suspension - trimethoprim pyrimidine active 80.0 mg/ml; sulfadiazine sulfanyl active 400.0 mg/ml - antibiotic & related - cattle | horse | pigs | sheep ewe - dry | beef | boar | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | co - bacterial infection | infections of the alimentary tract | infections of the respiratory tract | infections of the urogenital tract | acute respiratory infections | amoxycillin sensitive bacteria | associated with viral disease | bronchiseptica | bronchitis | cystitis | gram negative organisms | gram positive organisms | metritis | nephritis | pharyngitis | pneumonia | post parturient bacterial infe | primary bacterial infection | sulfadiazine sensitive bacteri | tonsillitis | trimethoprim sensitive bacteri | tylosin sensitive bacteria

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

the wellness center for research - horseradish (unii: 8ds6g120hj) (horseradish - unii:8ds6g120hj), taraxacum officinale (unii: 39981fm375) (taraxacum officinale - unii:39981fm375), tabebuia impetiginosa bark (unii: 6gla1946wx) (handroanthus impetiginosus bark - unii:6gla1946wx), brucella abortus (unii: 492lcm0tul) (brucella abortus - unii:492lcm0tul), escherichia coli (unii: 514b9k0l10) (escherichia coli - unii:514b9k0l10), germanium (unii: 00072j7xws) (germanium - unii:00072j7xws), human sputum, bordetella pertussis infected (unii: u3 - tired, rash, flu-like symptoms, swelling, joint pain, tingling, numbness in your hands, feet or back, brain fog, poor memory, weakness or paralysis in facial muscles. tired, rash, flu-like symptoms, swelling, joint pain, tingling, numbness in your hands, feet or back, brain fog, poor memory, weakness or paralysis in facial muscles.

Аустралија - Енглески - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - enrofloxacin - parenteral liquid/solution/suspension - enrofloxacin antibiotic active 50.0 mg/ml - antibiotic & related - animal - exotic | cat | dog | avian species | bitch | castrate | cat - queen | cat - tom | exotic animals | kitten | puppy | rep - antibiotics - oral, parenteral | infections of the respiratory tract | infections of the urinary tracts | staphylococcus intermedius | wound infections | abscesses | acute respiratory infections | airsacculitis | amoxycillin sensitive bacteria | anaerobic bacterial infection | avian mycoplasmas | bronchiseptica | bronchitis | clavulanic acid sensitive | coccidiosis | coryza | crd | deep pyodermas | dermatoses | diarrhoea | endometritis | enteritis | enzootic pneumonia | escherichia coli | european brood disease | gentamicin sensitive | group d streptococcus | hypermotility | including secondary invaders | infected wounds | infections | klebsiella spp. | lactating | mastitis | pharyngitis | pneumonia | proteus spp. | protozoal infections | pseudomonas aeruginosa | pyometra | salmonellosis | seborrhoeic dermatitis | sinusitis | staphylococcus spp. | systemic bacterial infection | tonsillitis